TARS News and Press, Tarsus Pharmaceuticals Inc. From 11/09/21

On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis; topline data expected in the first quarter of 2022 Data from two pioneering studies on prevalence and impact of Dem...

Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups New Titan study data analysis showed that current management tools, such as tea tree oil (TT...

IRVINE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D...

Tarsus Pharmaceuticals (NASDAQ:TARS) has filed for an up to $300M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Find out more about phase 2b/3 results presented on the company's lead candidate, TP-03 (lotilaner ophthalm...

LianBio, which has clinical candidates in several therapeutic areas, has set terms for its $325M initial public offering. The offering is for 20,312,500 American Depository Receipts representing 20,312,500 ordinary shares with the share price between $15 and $17. The company has applied ...

Biotech companies’ increasing focus on integrating advanced technology into their research projects to develop viable drugs for treating various critical diseases, and growing demand from an aging population, should drive the biotech industry’s growth. In addition to the industr...

Biotechnology is advancing rapidly, driven by robust investments in new developments and a demand for synthetic biology. The industry is expected to continue to generate significant growth over an extended period. Therefore, Wall Street analysts expect Tarsus (TARS) and Cidara (CDTX) to deliv...

Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries IRVINE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biop...

Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) conference Initiated Saturn-2, second pivotal Phase 3 trial evaluating the ...

Yuliya Starikova/iStock via Getty Images Tarsus Pharmaceuticals (TARS) announces new data from its Saturn-1 Phase 2b/3 trial and the Titan real-world collarette prevalence study at the ASCRS 2021 Annual Meeting. The new Saturn-1 data reinforce the strong potential clinical utility of TP-03 (l...